Xenon Pharmaceuticals Inc (XENE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.98B
Last updated: Nov 17, 2026 at 4:40 PM ET
Xenon Pharmaceuticals Inc (XENE) Stock Chart
Xenon Pharmaceuticals (XENE) has a latest price of $38.78 on Nov 17, 2026, 46.6% below its 52-week high of $72.66. Its price fell 4.9% over the past 12 months. The month-end price rose 392.2% over the 10 years through Oct 2026, a compound annual rate of 17.3%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $62.67 in Jul 2026 and its lowest $2.45 in Nov 2017, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart XENE with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for XENE.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 37.8%, and over 6 months it fell 28.3%. The month-end price rose 20.7% over the 3 years through Oct 2026, a compound annual rate of 6.5%.
| Period | Change |
|---|---|
| 1 month | +10.5% |
| 3 months | -37.8% |
| 6 months | -28.3% |
| 12 months | -4.9% |
| 12 months, with dividends | -4.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +20.7% | +6.5% |
| 5 years | +20.1% | +3.7% |
| 10 years | +392.2% | +17.3% |
Price by Year
Its best calendar year was 2018, when the price rose 123.4%, and its weakest was 2017, when it fell 63.3%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $37.41 | -16.5% |
| 2025 | $44.82 | +14.3% |
| 2024 | $39.20 | -14.9% |
| 2023 | $46.06 | +16.8% |
| 2022 | $39.43 | +26.2% |
| 2021 | $31.24 | +103.1% |
| 2020 | $15.38 | +17.3% |
| 2019 | $13.11 | +107.8% |
| 2018 | $6.31 | +123.4% |
| 2017 | $2.83 | -63.3% |
Trading Range
The price is 3.8% below its 50-day average of $40.30 and 25.8% below its 200-day average of $52.25.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $38.78 | |
| 52-week high | $72.66 | -46.6% |
| 52-week low | $33.38 | +16.2% |
| 50-day average | $40.30 | -3.8% |
| 200-day average | $52.25 | -25.8% |
Price Risk
Over 3 years, its largest fall from a peak was 52.8%.
| Measure | Value |
|---|---|
| 1-year beta | 0.80 |
| Largest fall, 1 year | -52.8% |
| Largest fall, 3 years | -52.8% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About XENE
What is XENE's 1-year price change?
Xenon Pharmaceuticals's price fell 4.9% over the past 12 months. With dividends included, the 12-month total return was -4.9%.
What is XENE's 5-year price change?
Xenon Pharmaceuticals's month-end price rose 20.1% over the 5 years through Oct 2026, a compound annual rate of 3.7%. These figures leave out dividends.
What is XENE's 52-week high and low?
Xenon Pharmaceuticals's 52-week high is $72.66 and its 52-week low is $33.38. Its latest price of $38.78 on Nov 17, 2026 is 46.6% below the high.
What is XENE's beta?
Xenon Pharmaceuticals's 1-year beta against the S&P 500 is 0.80, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 52.8%.
Is the XENE chart free?
Yes. Advanced Charting for XENE is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
XENE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors